Immuno-Oncology

The AJMC^® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

Travis Osterman, DO, MS, FAMIA, FASCO

Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

By Maggie L. Shaw

October 25th 2024

The theme of our recent Nashville Institute for Value-Based Medicine® event was ”Bringing the Future to the Present in Cancer Care.”

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

By Alana Hippensteele

September 15th 2024

Rates of ICI-related CVAEs and myocarditis were low, but the risk of mortality following CVAEs is high, underscoring the need for monitoring and management of these effects. | Image credit: Henadzy - stock.adobe.com

Early Recognition, Action Crucial for ICI-Induced Cardiovascular Adverse Effects

By Rose McNulty

August 30th 2024

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

By Mary Caffrey

August 24th 2024

Jeff Patton, MD | Image: OneOncology

OneOncology Announces Deal to Acquire United Urology Group

By Mary Caffrey

August 20th 2024

ASCO 2024: Latest Data in Melanoma

Gain expert insights to the phase 3 NADINA trial and learn more about unmet needs in melanoma management with this Post Conference Perspectives.

Gain expert insights to the phase 3 NADINA trial and learn more about unmet needs in melanoma management with this Post Conference Perspectives.

More News

April 10th 2017

Do We Need Biomarkers to Predict Tumor Hyper-Progression Following Immunotherapy?

Surabhi Dangi-Garimella, PhD

A new study published in Clinical Cancer Research provides evidence that researchers can use biomarkers to identify patients whose tumors will grow at a faster rate following immunotherapy treatment.

March 7th 2017

Study Compares Cost-Effectiveness of Immune Checkpoint Inhibitors in Advanced Melanoma

First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.

January 24th 2017

Study Reveals Why Immuno-Oncology Treatments Are Effective in Only a Minority of Patients

Surabhi Dangi-Garimella, PhD

A system-wide immune response, not just a local response limited to the tumor, is what determines successful remission following cancer immunotherapy.

January 17th 2017

MYSTIC Trial, Evaluating Durvalumab as First-Line in NSCLC, Adds OS Endpoint

Surabhi Dangi-Garimella, PhD

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

November 23rd 2016

5 Key Highlights From the Patient-Centered Oncology Care Meeting

Surabhi Dangi-Garimella, PhD

Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology CareÂ® meeting had in store for its attendees.

November 21st 2016

PCOC16: Immunoâ€Oncology Agents in a World of Precision Medicine

Surabhi Dangi-Garimella, PhD

At the 5th annual meeting of Patient-Centered Oncology CareÂ®, hosted by The American Journal of Managed Care, November 17-18 in Baltimore, Maryland, experts with diverse experiences and backgrounds discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

November 7th 2016

Meta-Analysis Confirms Clinical Advantage of BRAF/MEK and PD-1 Inhibitors in Melanoma

Surabhi Dangi-Garimella, PhD

Based on a retrospective meta-analysis of clinical trial data, authors of a recent paper in JAMA Oncology concluded that BRAF/MEK and programmed death receptor-1 (PD-1) inhibitors were the most effective treatments that were relatively safe in melanoma.

October 31st 2016

Phase I Study Indicates Pembrolizumab an Option in Heavily Pretreated Hodgkin Lymphoma

A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.

October 28th 2016

Study Results Could Help Strengthen Response to Checkpoint Inhibitors

Surabhi Dangi-Garimella, PhD

An animal study conducted at the Perelman School of Medicine, University of Pennsylvania, has identified a mechanism to strengthen the immune response of T cells in cancer patients who are treated with checkpoint inhibitors.

October 25th 2016

Pembrolizumab Is FDA-Approved as First-Line for PD-L1—Positive NSCLC

Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda).

October 19th 2016

First PD-L1 Inhibitor Approved as Second-Line Treatment for NSCLC

Surabhi Dangi-Garimella, PhD

Atezolizumab, an inhibitor of the programmed death ligand-1 protein, has been approved for the treatment of patients with non-small cell lung cancer who failed to respond to treatment with platinum-based chemotherapy.

October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.

October 5th 2016

Following Nivolumab, NICE Rejects Pembrolizumab for Use in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

A draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejected use of Merck's programmed death-1 inhibitor pembrolizumab (Keytruda) in patients diagnosed with non-small cell lung cancer (NSCLC).

October 4th 2016

The Power of an Immuno-oncology Collaborative Care Team

Surabhi Dangi-Garimella, PhD

At the Institute for Clinical Immuno-Oncology National Conference, a panel of care providers presented institutional experiences with immunotherapy, and how a collaborative care approach helped the process.

October 3rd 2016

Remarkable Outcomes With Cancer Immunotherapy, but Clinical Adoption Remains Challenging

Surabhi Dangi-Garimella, PhD

The cancer community has seen tremendous progress in the field of immunotherapy. However, educating patients and care providers across healthcare on this new tool remains a significant challenge.

September 9th 2016

5 Recent Developments in Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

An update on some of the recent developments in the field of immuno-oncology.

September 7th 2016

Pembrolizumab's Breakthrough Toughens the Playing Field in NSCLC

Surabhi Dangi-Garimella, PhD

The FDA has accepted for priority review the supplemental Biologics License Application for Merck's pembrolizumab (Keytruda).

August 3rd 2016

Nivolumab Passes QOL Test in Melanoma

Surabhi Dangi-Garimella, PhD

Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab performs well in improving patients' long-term quality of survival benefit in patients with advanced melanoma.

July 14th 2016

NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 Inhibitor—Treated Melanoma

Surabhi Dangi-Garimella, PhD

Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin gene were found responsible for lack of response to interferon gamma.

July 14th 2016

Zeroing in on Predictive Biomarkers for Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

During a clinical session at the annual meeting of the American Society of Clinical Oncology, researchers were tasked with sharing their data on any breakthroughs or leads with biomarkers for the new immunotherapies.

July 14th 2016

CAR-T Cells in Leukemia and Lymphoma

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology, results were presented from a phase 1/2 trial in which patients with relapsed or refractory CD19+ B-cell malignancies were treated with CD19 CAR-T cells.

July 13th 2016

Promising Results With Combination Immunotherapy in Solid Tumors and Leukemia

Surabhi Dangi-Garimella, PhD

As immunotherapy-particularly the checkpoint inhibitors-continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination to improve efficacy and outcomes.

July 13th 2016

Nivolumab Safe in Glioblastoma

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Clinical Oncology, held June 3-7, 2016, phase 1 data from the CheckMate 143 trial was presented during a poster session.

May 27th 2016

5 Things to Look for at the Annual ASCO 2016 Meeting

Surabhi Dangi-Garimella, PhD

The patient will be the focus during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), Collective Wisdom: The Future of Patient-Centered Care and Research.

April 19th 2016

Companion Diagnostic Tests for Immunotherapy Could Be Switched

Surabhi Dangi-Garimella, PhD

A study presented at the ongoing annual meeting of the American Association for Cancer Research has confirmed that 3 commercially available diagnostic tests that measure the expression of the programmed death ligand 1 protein in non-small cell lung cancer could be interchanged.

April 5th 2016

The Promise of Cancer Immunotherapy: Why Patient Education Is Critical, Part II

It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.

March 31st 2016

NCCN Melanoma Guideline Update: It's About Immunotherapy and Targeted Therapy

Surabhi Dangi-Garimella, PhD

At the National Comprehensive Cancer Network 21st Annual Conference, John A. Thompson, MD, presented an update on where the field of melanoma treatment stands today.

March 29th 2016

The Promise of Cancer Immunotherapy: Why Patient Education Is Critical, Part I

It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.

March 17th 2016

Adverse Dermal Effects of PD-1 Inhibitors: Surrogate for Better Response?

Surabhi Dangi-Garimella, PhD

A new study in Australia adds to the evolving knowledge on adverse cutaneous effects of pembrolizumab and nivolumab. Could they also indicate better prognosis?

March 16th 2016

Atezolizumab: Another Novel IO Agent Faces Challenges With Enriching for Responders

Surabhi Dangi-Garimella, PhD

FDA has granted a Priority Review designation for the breakthrough programmed death ligand-1 inhibitor atezolizumab, for the treatment of bladder cancer.

...

9 10 11 12 13 14 15 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions